Dasatinib Monohydrate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Dasatinib Monohydrate |
| DrugBank ID | DB01254 |
| Brand Names (EU) | Dasatinib Accord Healthcare |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.90% |
Approved Indication (EMA)
Dasatinib Accord Healthcare is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib. Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Dasatinib Accord Healthcare is indicated for the treatment of paediatric pat
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Ewing sarcoma | 99.90% | DL |
| 2 | myeloid leukemia | 99.68% | DL |
| 3 | liposarcoma | 99.67% | DL |
| 4 | fibromatosis, gingival | 99.65% | DL |
| 5 | dermatofibrosarcoma protuberans | 99.65% | DL |
| 6 | ovarian myxoid liposarcoma | 99.59% | DL |
| 7 | ganglioneuroblastoma (disease) | 99.59% | DL |
| 8 | vertebral anomalies and variable endocrine and T-cell dysfunction | 99.59% | DL |
| 9 | inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia | 99.58% | DL |
| 10 | hamartoma of lung | 99.56% | DL |
| 11 | fibroma of lung | 99.55% | DL |
| 12 | junctional epidermolysis bullosa | 99.53% | DL |
| 13 | lung benign neoplasm | 99.52% | DL |
| 14 | Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome | 99.52% | DL |
| 15 | lung hilum carcinoma | 99.50% | DL |
| 16 | lung cancer | 99.48% | DL |
| 17 | retroperitoneal neoplasm | 99.48% | DL |
| 18 | neuroblastoma | 99.48% | DL |
| 19 | pulmonary sulcus neoplasm | 99.47% | DL |
| 20 | lung germ cell tumor | 99.47% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.